ArticleLeukemia2024
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Molecular Abnormalities and Associated Clinical Features in Polycythemia Vera.Medical sciences (Basel, Switzerland) · 2026Review
- Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.Leukemia · 2026Article
- Clinical Impact of Next-Generation Sequencing-Detected Mutations on Thrombotic Events in Myeloproliferative Neoplasms.International journal of laboratory hematology · 2026Article
- Preserving thrombosis and life years in polycythemia vera: start by reading the biology of the disease.Haematologica · 2026Article
- Prognostic Scores and Risk Stratification of Myeloproliferative Neoplasms: 2026 Updates.Cancers · 2026Review
- Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.Blood cancer journal · 2026Article
- Modern and multidisciplinary care in polycythemia vera.Annals of hematology · 2026Review
- Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.Leukemia · 2026Article
- Outcomes of patients with myeloproliferative neoplasms and critical limb ischemia: insights from the National readmissions database.Journal of thrombosis and thrombolysis · 2025Article
- Validation and interpretation of the Triple A model in Turkish myeloproliferative neoplasm patients with a focus on overall and thrombosis free survival.Journal of hematopathology · 2025Article
- Clinical and Molecular Insights of Arterial and Venous Thrombosis in Myeloproliferative Diseases-Case-Based Narrative Review.Biomedicines · 2025Review
- Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms.Annals of hematology · 2025Article
- Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis.Annals of hematology · 2025Article
- Polycythaemia vera.Nature reviews. Disease primers · 2025Review
- Construction and validation of a predictive model for postoperative stent occlusion in patients undergoing iliac vein stenting based on an explainable machine learning model.Frontiers in surgery · 2025Article
- Unravelling the role of TET2 in venous thromboembolism: insights into mechanisms and therapeutic implications.Frontiers in cardiovascular medicine · 2025Review
- Article
- Myeloproliferative neoplasms: young patients, current data and future considerations.Annals of hematology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current recommended risk scores to predict thrombotic events associated with myeloproliferative neoplasms (MPN) do not discriminate between arterial and venous thrombosis despite their different physiopathology. To define novel stratification systems, we delineated a comprehensive landscape of MPN associated thrombosis across a large long-term follow-up MPN cohort. Prior arterial thrombosis, age >60 years, cardiovascular risk factors and presence of TET2 or DNMT3A mutations were independently associated with arterial thrombosis in multivariable analysis. ARTS, an ARterial Thrombosis Score, based on these four factors, defined low- (0.37% patients-year) and high-risk (1.19% patients-year) patients. ARTS performance was superior to the two-tiered conventional risk stratification in our training cohort, across all MPN subtypes, as well as in two external validation cohorts. Prior venous thrombosis and presence of a JAK2
Indexed as
Identifiers
38148396What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.